Figure S1. Treatment Plan.

Table S1. Characteristics of 366 AML patients, incidence of molecular mutations (*NPM1* and *FLT3*).

Overall		Number (%)
		366
Sex	male	203 (55.5)
	female	163 (44.5)
NPM1	mutated	132/327 (40.4)
	unmutated	195/327 (59.6)
	not available	39/366 (10.6)
FLT3	mutated	98/352 (27.8)
FLT3-ITD	mutated	65/352 (18.5)
	unmutated	287/352 (81.5)
	not available	14/366 (3.8)
FLT3-TKD	mutated	33/316 (10.4)
	unmutated	28/316 (8.9)
	not available	50/366 (13.6)
NPM1/*FLT3*-ITD	*NPM1* m/*FLT3*-ITD wt	73/138 (52.9)
	NPM1 m/*FLT3*-ITD m	38/138 (27.5)
	NPM1 wt/*FLT3*-ITD m	27/138 (18.6)
Karyotype Risk Classification*	favorable	38 (10.4)
	intermediate	265 (72.4)
	adverse	59 (16.1)
	not available	4 (1.1)

Abbreviations: wt: wild-type; m: mutated.

Notes: *according to MRC [22].